New findings on glucagon synthesis

Researchers at Karolinska Institutet in Sweden have shown that the cells that produce glucagon are stimulated by the hormone itself. A previous study by the same group demonstrated that this principle also applies to insulin. This means that a feedback system is at work in the body, whereby hormone secreting cells receive an immediate signal to produce more of the hormone.

While insulin is a hormone that lowers the level of glucose in the blood, glucagon is a hormone that increases it. Associate Professors Barbara and Ingo Leibiger and Professor Per-Olof Berggren at Karolinska Institutet have already published results showing that the insulin-producing cells are activated by the very hormone they release. Whether this process applies only to insulin or whether it reflects a general biological principle for all hormone-secreting cells has, however, remained unclear.

Now, the same team have shown that glucagon can also stimulate its own synthesis. This it does by binding to a specific on the glucagon-secreting cells in the pancreas, where it subsequently influences a number of signalling pathways that lead to the activation of the gene that produces . It thus seems that the positive-feedback process, whereby secreted hormones affect their own production, has general .

"Learning about how the hormones regulate their own production will eventually enable us to study defects in this process, and if these defects are implicated in diabetes, then an important piece of the puzzle might well be in place," says Per-Olof Berggren.

More information: 'Glucagon regulates its own synthesis by autocrine signaling', Barbara Leibiger, Tilo Moede, Thusitha P. Muhandiramlage, Daniel Kaiser, Pilar Vaca Sanchez, Ingo B. Leibiger, and Per-Olof Berggren, Proceedings of the National Academy of Sciences (PNAS), Early Edition 3-7 December 2012.

Related Stories

New research redraws pancreas anatomy

Jul 06, 2011

(Medical Xpress) -- Research from Karolinska Institutet shows that insulin secretion in the pancreas is not under direct neural control, as has previously been thought. The few nerves that are present are connected to blood ...

Recommended for you

Researcher studies protein's link to heart disease

Jun 18, 2013

(Medical Xpress)—The largest protein known to exist in the human body functions as a molecular spring, and University of Arizona researchers are gaining new insights into its role in heart disease.

The rhythm of everything

Jun 18, 2013

Dawn triggers basic biological changes in the waking human body. As the sun rises, so does heart rate, blood pressure and body temperature. The liver, the kidneys and many natural processes also begin shifting ...

User comments

More news stories

Laughing gas does not increase heart attacks

(Medical Xpress)—Nitrous oxide—best known as laughing gas—is one of the world's oldest and most widely used anesthetics. Despite its popularity, however, experts have questioned its impact on the risk ...

Model recreates wear and tear of osteoarthritis

(Medical Xpress)—There's a reason osteoarthritis is often called wear-and-tear arthritis: Repeated stress on joints over time results in degeneration of the soft cartilage that normally distributes loads ...

Taxing unhealthy food spurs people to buy less

Labeling foods and beverages as less-healthy and taxing them motivates people to make healthier choices, finds a recent study in the American Journal of Preventive Medicine. When faced with a 30 percent tax on ...

Renewed hope in a once-abandoned cancer drug class

Could drugs that block the body's system for repairing damage to the genetic material DNA become a boon to health? As unlikely as it may seem, those compounds are sparking optimism as potential treatments ...

New technologies for retinal therapies

The future of the investigation and treatment of retinal disorders is already here at the MedUni Vienna: in the new Christian Doppler "OPTIMA" (Ophthalmic Image Analysis) laboratory headed by Ursula Schmidt-Erfurth, ...

Protalix signs supply deal with Brazilian govt

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...